Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MBS314
- Development stage
- Phase 2
- Lead developer
- Mabworks Biotech
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MBS314 is a humanized trispecific antibody designed for the treatment of relapsed and/or refractory multiple myeloma (RRMM). It simultaneously targets and binds to B-cell maturation antigen (BCMA) and G protein-coupled receptor family C group 5 member D (GPRC5D) on tumor cells, as well as CD3 on T cells. This enables the recruitment and activation of T cells to kill myeloma cells expressing either BCMA or GPRC5D, thereby overcoming tumor heterogeneity in RRMM. The drug demonstrates linear pharmacokinetics with a half-life supporting weekly or biweekly dosing. Developed by Beijing Mabworks Biotech in collaboration with Kangyuan Botron Biotechnology, MBS314 is currently being evaluated in Phase 1/2 clinical trials in China[2][4][5][6].
- Other names
- anti-BCMA/GPRC5D/CD3 trispecific antibody
02
Targets
GPRC5DBCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on MBS314.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MBS314.